No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CORT Corcept Therapeutics
- 23.880
- +0.560+2.40%
Close May 1 16:00 ET
- 27.130
- +3.250+13.61%
Post 19:18 ET
2.48BMarket Cap25.40P/E (TTM)
24.610High22.600Low1.83MVolume23.090Open23.320Pre Close43.84MTurnover2.15%Turnover Ratio25.40P/E (Static)103.84MShares34.27552wk High4.89P/B2.03BFloat Cap20.84052wk Low--Dividend TTM85.09MShs Float34.275Historical High--Div YieldTTM8.62%Amplitude0.680Historical Low23.978Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024
Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.
Corcept Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Increased FY24 Revenue Guidance Above Estimates.
Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est
Corcept Therapeutics Increases FY24 Revenue Guidance From $600M-$630M To $620M–$650M Vs $610.64M Est
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, Vs. Street Est of $0.22
04:12 PM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22
Corcept Therapeutics Raises 2024 View To Rev $620M-$650M >CORT
Corcept Therapeutics Raises 2024 View To Rev $620M-$650M >CORT
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg